Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Feb 19.
doi: 10.1038/s44318-026-00712-4. Online ahead of print.

TRPML1 suppresses pulmonary fibrosis by limiting collagen and elastin deposition

Affiliations
Free article

TRPML1 suppresses pulmonary fibrosis by limiting collagen and elastin deposition

Eva-Maria Weiden et al. EMBO J. .
Free article

Abstract

In pulmonary fibrosis lung tissue is thickened and scarred, and the lungs become progressively stiffer and smaller, leading to low levels of blood oxygen and shortness of breath. Lung fibrosis is not curable and life expectancy is reduced. Fibrosis is characterized by an increased accumulation of extracellular matrix (ECM) proteins such as collagen and elastin. ECM proteins are degraded predominantly by matrix metalloproteinases (MMPs). Here, we show that the lysosomal cation channel TRPML1, which causes the lysosomal storage disorder mucolipidosis type IV (MLIV) when mutated or lost, regulates the levels of MMPs in the ECM of mouse airways, modulating exocytosis of MMP2, 8, 9, 12, and 19, which mediate collagen/elastin degradation. While TRPML1 loss reduces MMP levels in lung macrophage and fibroblast supernatants, small molecule activation of TRPML1 results in increased levels. MLIV mice display a fibrosis-like lung phenotype similar to the phenotype evoked by bleomycin. We thus identify TRPML1 as a regulator of MMP release in the lung with loss of TRPML1 resulting in lung fibrosis due to excessive extracellular collagen and elastin accumulation.

Keywords: Mcoln1; Pulmonary Fibrosis; TRPML; TRPML1; TRPML3.

PubMed Disclaimer

Conflict of interest statement

Disclosure and competing interests statement. SK has received honoraria from Plectonic, TCR2 Inc., Miltenyi, Galapagos, Cymab, Novartis, Regeneron, BMS, and GSK. SK is an inventor of several patents in the field of immuno-oncology. SK and SE received license fees from TCR2 Inc. and Carina Biotech. SK received research support from TCR2 Inc., Tabby Therapeutics, Catalym GmbH, Plectonic GmbH, and Arcus Bioscience for work unrelated to the manuscript. The remaining authors declare no competing interests. JG-F and LOM are employees of Casma Therapeutics, 201 Brookline Ave, Boston, MA, USA, 02215.

References

    1. Afratis NA, Selman M, Pardo A, Sagi I (2018) Emerging insights into the role of matrix metalloproteases as therapeutic targets in fibrosis. Matrix Biol 68–69:167–179 - PubMed - DOI
    1. Arpino V, Brock M, Gill SE (2015) The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol J Int Soc Matrix Biol 44–46:247–254 - DOI
    1. Bach G, Zeevi DA, Frumkin A, Kogot-Levin A (2010) Mucolipidosis type IV and the mucolipins. Biochem Soc Trans 38:1432–1435 - PubMed - DOI
    1. Baidya SK, Banerjee S, Guti S, Jha T, Adhikari N (2024) Matrix metalloproteinase-8 (MMP-8) and its inhibitors: a minireview. Eur J Med Chem Rep 10:100130
    1. Balbín M, Fueyo A, Knäuper V, López JM, Alvarez J, Sánchez LM, Quesada V, Bordallo J, Murphy G, López-Otín C (2001) Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 276:10253–10262 - PubMed - DOI

LinkOut - more resources